Alumis (NASDAQ:ALMS – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Alumis to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.
Profitability
This table compares Alumis and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alumis | -5,844.54% | -89.77% | -71.50% |
| Alumis Competitors | -12,224.09% | -202.33% | -31.23% |
Analyst Recommendations
This is a summary of recent ratings for Alumis and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alumis | 1 | 1 | 11 | 1 | 2.86 |
| Alumis Competitors | 9919 | 15313 | 45657 | 1602 | 2.54 |
Alumis presently has a consensus price target of $32.09, suggesting a potential upside of 473.05%. As a group, “Biotechnology” companies have a potential upside of 126.35%. Given Alumis’ stronger consensus rating and higher possible upside, equities analysts plainly believe Alumis is more favorable than its competitors.
Insider and Institutional Ownership
47.8% of shares of all “Biotechnology” companies are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Alumis and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Alumis | $7.40 million | -$243.32 million | -1.59 |
| Alumis Competitors | $740.58 million | $10.45 million | -18.80 |
Alumis’ competitors have higher revenue and earnings than Alumis. Alumis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Alumis has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. Comparatively, Alumis’ competitors have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.
Summary
Alumis beats its competitors on 9 of the 13 factors compared.
Alumis Company Profile
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
